Interim analysis of LIGHT study of Contrave (naltrexone HCl/bupropion) in CV Risk with obese patients- Orexigen/Takeda
The LIGHT Study which the FDA had asked Orexigen not to disclose (but whose results were disclosed with a new patent application) enrolled approximately 8900 patients who were treated with Contrave (naltrexone HCl/bupropion) or placebo. LIGHT study has shown in interim results that people treated with Contrave, particularly smokers and people with diabetes for less than 6 years, had a lower risk of adverse CV events than those on placebo. The risk of death was cut by 41% for patients who received Contrave.There were 24 myocardial infarctions (heart attacks) in the Contrave arm versus 34 in the placebo arm (HR=0.70; p<0.0001); seven versus 11 strokes (HR=0.63; p=0.0088); and five versus 19 cardiovascular deaths (HR=0.26; p<0.0001). A further cardiovascular outcomes trial is to proceed.
Comment: The positive interim results have to be sustained as the study proceeds and there were a high rate of discontinuations seen in the trial (62% of Contrave patients). The FDA considers that it is too early to draw conclusions from the trial.
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.